R
|
esearchers have found that ketamine
can act quickly to relieve symptoms of severe depression, but it remains
unclear how. A new study asks whether this drug is just "another
opioid" in disguise and advises specialists to exercise caution.
Ketamine may be able to relieve
depression symptoms quickly, but we do not yet fully understand this drug's
danger.
Earlier
this year, Medical News Today reported
on research that found that ketamine can quickly
relieve symptoms of severe depression, such as suicidal thoughts.
That
being said, researchers are still working to understand what makes ketamine so
effective, and even more importantly, whether the temporary relief it provides
is worth it compared with side effects such as dissociation and risks such
as addiction.
Some
studies have suggested that ketamine's effect on symptoms of depression is due
to its NMDA receptor antagonist properties, which also allow it
to work as an anesthetic.
Now, a study published in the American Journal of Psychiatry says that ketamine's antidepressantproperties are due to the
fact that it activates the opioid system.
The
opioid system is made of opioid receptors found in the brain, and these
receptors react to opioid drugs, such as morphine, which are highly
addictive.
In
the new study, Drs. Nolan Williams, Boris Heifets, and team from Stanford University
in California explored how ketamine's interaction with the opioid system
affects its antidepressant properties and dissociative effects in people with
depression who are resistant to traditional treatments.
Testing whether ketamine acts like an opioid
The
researchers based the study — a randomized double-blind crossover trial — on
the hypothesis that ketamine interacts with opioid receptors. To test this
idea, they wanted to see how an opioid blocker called naltrexone would
interfere with ketamine's effects on depression.
Dr.
Williams and team recruited 30 participants with treatment-resistant
depression. All were enrolled to receive ketamine for their symptoms; however,
some also received naltrexone beforehand, while others took a placebo.
Of
all of the participants, 12 took both naltroxene plus ketamine, and a placebo
plus ketamine, in random order.
The researchers found that taking naltroxene before
ingesting ketamine lessened or blocked the drug's antidepressant effects, but
not the sensation of dissociation that it induced.
Due
to these outcomes, the researchers had to put a stop to the trial early to
safeguard the participants' well-being.
'We should be cautious' about ketamine
The editorial that accompanies the study paper warns that
ketamine comes with unknown risks for health and urges researchers to delve
deeper into the mechanisms that this drug sets in motion.
"We
would hate to treat the depression and suicide epidemics by overusing ketamine,
which might perhaps unintentionally grow the third head of opioid
dependence," writes the editorial's author Dr. Mark George, from the
Medical University of South Carolina in Charleston.
"[W]ith these new findings, we
should be cautious about widespread and repeated use of ketamine before further
mechanistic testing has been performed to determine whether ketamine is merely
another opioid in a novel form."
Dr. Mark
George
In
the future, Dr. George also suggests, researchers may want to also invest more
time in studying some other underused treatments for depression, such as
electroconvulsive therapy, transcranial magnetic stimulation, and vagus nerve
stimulation.
No comments:
Post a Comment